{
    "startDate": "2021-01-01",
    "endDate": "2021-03-31",
    "year": "2021",
    "quarter": "Q1",
    "symbol": "EYES",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 26862000
            },
            {
                "label": "Prepaid expenses and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 759000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 27621000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 154000
            },
            {
                "label": "Right-of-use assets, net",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 351000
            },
            {
                "label": "Represents the information pertaining to deposits and other assets.",
                "concept": "eyes:DepositsAndOtherAssets",
                "unit": "usd",
                "value": 19000
            },
            {
                "label": "ASSETS",
                "concept": "Assets",
                "unit": "usd",
                "value": 28145000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1607000
            },
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 1220000
            },
            {
                "label": "Accrued compensation expense",
                "concept": "EmployeeRelatedLiabilitiesCurrent",
                "unit": "usd",
                "value": 199000
            },
            {
                "label": "Represents information pertaining to accrued clinical trial expenses.",
                "concept": "eyes:AccruedClinicalTrialExpenses",
                "unit": "usd",
                "value": 1212000
            },
            {
                "label": "Current operating lease liabilities",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 167000
            },
            {
                "label": "Current debt",
                "concept": "DebtCurrent",
                "unit": "usd",
                "value": 2200000
            },
            {
                "label": "Contract liabilities",
                "concept": "ContractWithCustomerLiabilityCurrent",
                "unit": "usd",
                "value": 335000
            },
            {
                "label": "Current liabilities:",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 6940000
            },
            {
                "label": "Long term operating lease liabilities",
                "concept": "OperatingLeaseLiabilityNoncurrent",
                "unit": "usd",
                "value": 199000
            },
            {
                "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 7139000
            },
            {
                "label": "Commitments and contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Preferred stock, no par value, 10,000 shares authorized; none outstanding",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 27,908 and 23,214 as of March 31, 2021 and December 31, 2020, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 294592000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 49333000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -412000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -322507000
            },
            {
                "label": "Stockholders\u2019 equity (deficit):",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 21006000
            },
            {
                "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 28145000
            }
        ],
        "cf": [
            {
                "label": "Net loss",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -2843000
            },
            {
                "label": "Depreciation",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 20000
            },
            {
                "label": "Stock-based compensation",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": 19000
            },
            {
                "label": "Non-cash lease expense",
                "concept": "OperatingLeaseExpense",
                "unit": "usd",
                "value": 16000
            },
            {
                "label": "Prepaid expenses and other assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": -332000
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": 1158000
            },
            {
                "label": "Accrued expenses",
                "concept": "IncreaseDecreaseInAccruedLiabilities",
                "unit": "usd",
                "value": 345000
            },
            {
                "label": "Accrued compensation expenses",
                "concept": "IncreaseDecreaseInEmployeeRelatedLiabilities",
                "unit": "usd",
                "value": 26000
            },
            {
                "label": "The increase (decrease) during the period in the carrying value of accrued clinical trial expenses reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
                "concept": "eyes:IncreaseDecreaseAccruedClinicalTrialExpenses",
                "unit": "usd",
                "value": 149000
            },
            {
                "label": "Cash flows from operating activities:",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -778000
            },
            {
                "label": "Proceeds from issuance of common stock and warrants.",
                "concept": "eyes:ProceedsFromIssuanceOfCommonStockAndWarrants",
                "unit": "usd",
                "value": 24466000
            },
            {
                "label": "Cash flows from financing activities:",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 24466000
            },
            {
                "label": "Effect of exchange rate changes on cash and cash equivalents",
                "concept": "EffectOfExchangeRateOnCashAndCashEquivalents",
                "unit": "usd",
                "value": -3000
            },
            {
                "label": "Net increase (decrease)",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": 23685000
            }
        ],
        "ic": [
            {
                "label": "Research and development, net of grants",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 334000
            },
            {
                "label": "Clinical and regulatory expense, net of grants.",
                "concept": "eyes:ClinicalAndRegulatoryExpenseNetOfGrants",
                "unit": "usd",
                "value": 37000
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 2472000
            },
            {
                "label": "Operating expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 2843000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -2843000
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -2843000
            },
            {
                "label": "Net loss per common share \u2013 basic and diluted",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -0.12
            },
            {
                "label": "Weighted average common shares outstanding \u2013 basic and diluted",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 23537000
            },
            {
                "label": "Foreign currency translation adjustments",
                "concept": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
                "unit": "usd",
                "value": 36000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -2807000
            }
        ]
    }
}